Outcomes summary

Pharmacokinetic and pharmacodynamic study in healthy men reporting that GHRH(1–29)-NH2 (sermorelin) is rapidly eliminated after intravenous administration, with associated growth hormone release; intranasal administration showed low bioavailability in this study.

Limitations

Older, early-phase physiology study; results may not generalize to clinical populations; dosing and routes studied are not guidance.

Notes

Primary source: PMID 8329825.